Stocks In Focus

Releasing details of the official minutes from the Breakthrough Therapy Type B Clinical Guidance meeting with the FDA regarding its Tonmya for the treatment of posttraumatic stress disorder, Tonix said the minutes were consistent with the guidance received at the meeting.

The company said plans to add an unblinded interim analysis that allows for a potential sample size adjustment.

Tonix said, having enrolled more than 50% of the current target number of participants, it expects to release results of the interim analysis in the first quarter of 2020. Top-line data is likely to be released in the second quarter of 2020.

The shares advanced 12.38% to $1.18 in after-hours trading.

Qiagen Says FDA Approves Latent TB Screening Test

Qiagen announced FDA approval for LIAISON QunatiFERON-TB Plus Test, which it has developed along with DiaSorin. The test is meant for streamlined laboratory automation for latent TB screening, supporting the conversion from tuberculin skin tests to modern blood-based QuantiFERON technology. The test is now commercially available in the U.S.

Offerings

Aravive Inc (NASDAQ: ARAV) commenced an underwritten public offering of its common stock. All the shares offered will be sold by Aravive. The company said it expects to use the net proceeds for R&D, development and manufacturing of product candidates, and for general corporate purposes.